Reduced FOXF1 links unrepaired DNA damage to pulmonary arterial hypertension-Reference-Cited by-同舟云学术

Reduced FOXF1 links unrepaired DNA damage to pulmonary arterial hypertension

Published:2023-11-21 Issue:1 Volume:14 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Isobe Sarasa^ORCID,Nair Ramesh V.,Kang Helen Y.,Wang Lingli,Moonen Jan-Renier,Shinohara Tsutomu,Cao Aiqin,Taylor Shalina,Otsuki Shoichiro^ORCID,Marciano David P.,Harper Rebecca L.^ORCID,Adil Mir S.^ORCID,Zhang Chongyang,Lago-Docampo Mauro^ORCID,Körbelin Jakob^ORCID,Engreitz Jesse M.^ORCID,Snyder Michael P.^ORCID,Rabinovitch Marlene^ORCID

Abstract

AbstractPulmonary arterial hypertension (PAH) is a progressive disease in which pulmonary arterial (PA) endothelial cell (EC) dysfunction is associated with unrepaired DNA damage. BMPR2 is the most common genetic cause of PAH. We report that human PAEC with reduced BMPR2 have persistent DNA damage in room air after hypoxia (reoxygenation), as do mice with EC-specific deletion of Bmpr2 (EC-Bmpr2-/-) and persistent pulmonary hypertension. Similar findings are observed in PAEC with loss of the DNA damage sensor ATM, and in mice with Atm deleted in EC (EC-Atm-/-). Gene expression analysis of EC-Atm-/- and EC-Bmpr2-/- lung EC reveals reduced Foxf1, a transcription factor with selectivity for lung EC. Reducing FOXF1 in control PAEC induces DNA damage and impaired angiogenesis whereas transfection of FOXF1 in PAH PAEC repairs DNA damage and restores angiogenesis. Lung EC targeted delivery of Foxf1 to reoxygenated EC-Bmpr2-/- mice repairs DNA damage, induces angiogenesis and reverses pulmonary hypertension.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary

Link

https://www.nature.com/articles/s41467-023-43039-y.pdf

Reference76 articles.

1. Humbert, M., et al. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur. Respir. J 2201347 (2022).

2. Lane, K. B. et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat. Genet. 26, 81–84 (2000).

3. Evans, J. D. et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir. Med. 4, 129–137 (2016).

4. Atkinson, C. et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 105, 1672–1678 (2002).

5. Alastalo, T.-P. et al. Disruption of PPARγ/β-catenin–mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J. Clin. Invest. 121, 3735–3746 (2011).